Know Cancer

or
forgot password

PIK3CA Mutation Status as a Biomarker in Elderly Women With Breast Cancer


N/A
70 Years
N/A
Not Enrolling
Female
Breast Cancer

Thank you

Trial Information

PIK3CA Mutation Status as a Biomarker in Elderly Women With Breast Cancer


OBJECTIVES:

- To validate PIK3CA mutation status as a biomarker in women 70 years or older diagnosed
with breast cancer.

OUTLINE: Genomic DNA extracted from archived tumor tissue samples are analyzed for mutation
by Sequenom multiplex massARRAY (multiplex PCR and mass spectroscopy). Results are then
analyzed by massARRAY TyperAnalyzer v4.0 software. Patients clinical data are also analyzed,
including treatment received.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Patients must have been registered to CALGB 9343

- Stage I disease

- Tumors ≤ 2 cm

- Estrogen-receptor positive (ER+)

- Lymph node negative

- Paraffin block or slides of the primary tumor must be available and have been
submitted to the CALGB Pathology Coordinating Office

PATIENT CHARACTERISTICS:

- Consented to future research participation

PRIOR CONCURRENT THERAPY:

- Not specified

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Breast cancer-free interval of patients with PIK3CA-mutated tumors as compared to wild-type tumors

Safety Issue:

No

Principal Investigator

Mary Ellen Moynahan, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

Unspecified

Study ID:

CDR0000699810

NCT ID:

NCT01346579

Start Date:

April 2011

Completion Date:

Related Keywords:

  • Breast Cancer
  • stage IA breast cancer
  • stage IB breast cancer
  • estrogen receptor-positive breast cancer
  • Breast Neoplasms

Name

Location